Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Group therapy may work as well as drugs to prevent depression relapse

(Reuters Health) – Group therapy may work as well as medication to help keep depression from returning for patients who have already taken drugs to control symptoms, a British study suggests.   Researchers studied what’s known as mindfulness-based cognitive therapy, a combination of group counseling sessions and meditation exercises. For people with a history of […]

Read More »

Does Your Job Make You Think? Your Brain Will Thank You Later

If your job is chock full of challenging thinking tasks, your brain may be getting a positive boost that will help prevent memory loss and thinking decline later in life, according to a new study. Adding to an already robust catalog of research showing that thinking-related challenges are like exercise for the brain, the latest […]

Read More »

Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority – CPAM

Nutra Pharma Has Announced That They Have Received Notification of the Acceptance of Nyloxin® by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM) CORAL SPRINGS, FL–(Marketwired – Apr 30, 2015) – Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), […]

Read More »

Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola

SAN DIEGO, April 30, 2015 /PRNewswire/ — Tamir Biotechnology, a leading developer of RNA modulating drugs, announced today an update on its Ebola antiviral therapy program. Clinical ProgressOne of Tamir’s leading candidates, TMR004, is currently being evaluated and considered by a number of clinicians on the frontline of the battle against Ebola. During the first quarter […]

Read More »

FDA panel recommends approval for Amgen’s skin cancer immunotherapy

(Reuters) – Amgen Inc’s skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or “T-Vec”, an engineered virus that kills cancer cells […]

Read More »

FDA Panel Gives Thumbs-Up To Amgen’s Virus-Based Melanoma Drug

Two days after the U.S. Food & Drug Administration signaled it might quash Amgen Inc.’s attempt to usher in a whole new class of virus-based cancer drugs, an advisory panel for the agency voted “yes” on the question of whether the company’s experimental melanoma treatment, talimogene laherparepvec (T-VEC), has a favorable enough risk-benefit profile for approval. […]

Read More »

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority Review for this application. The projected FDA […]

Read More »

AstraZeneca heart drug in regulatory fast lane for wider use

(Reuters) – U.S. regulators are to fast-track the review of a new use of AstraZeneca’s heart drug Brilinta, meaning it could get the green light in the third quarter to be given to patients with a history of heart attacks. The drugmaker said on Wednesday the decision by the Food and Drug Administration (FDA) reflected […]

Read More »

Celgene (CELG) Dealmaking Continues With Two Pacts Worth $110 Million With Northern Biologics, Agios (AGIO)

CAMBRDIGE, Mass. – Celgene Corporation (CELG) has struck two deals with other pharmaceutical companies with a combined value of $110 million to advance its oncology platform, continuing the cancer drugmaking company’s deal making trend to advance its oncology pipeline. Today Celgene announced it entered into an $80 million agreement with Agios Pharmaceuticals (AGIO) to develop […]

Read More »

Scientists race to beat mosquito resistance in fight against malaria: TRFN

Malaria tests are seen on a table in the Ta Gay Laung village hall in Hpa-An district in Kayin state, south-eastern Myanmar, November 28, 2014. Reuters/Astrid Zweynert LONDON (Thomson Reuters Foundation) – Mosquitoes are rapidly developing resistance to insecticides used in bed nets that millions of people rely on to protect them from malaria, experts […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom